Gedeon Richter (RICHTER) Stock Overview
Researches, develops, manufactures, markets, and sells pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
RICHTER Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Gedeon Richter PLC Competitors
NATURLAND Holding Vagyonkezelo es Befektetesi Nyilvanosan Mukodo Reszvenytarsasag
Ono Pharmaceutical
Glenmark Pharmaceuticals
GlaxoSmithKline Pharmaceuticals
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Ft9,900.00 |
| 52 Week High | Ft11,150.00 |
| 52 Week Low | Ft9,500.00 |
| Beta | 0.22 |
| 1 Month Change | -3.32% |
| 3 Month Change | -5.53% |
| 1 Year Change | -9.84% |
| 3 Year Change | 18.56% |
| 5 Year Change | 49.10% |
| Change since IPO | 5,400.00% |
Recent News & Updates
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Screens Well But There Might Be A Catch
Nov 06
The Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Half-Yearly Results Are Out And Analysts Have Published New Forecasts
Aug 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Looks Inexpensive But Perhaps Not Attractive Enough
Jul 22These 4 Measures Indicate That Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (BUSE:RICHTER) Is Using Debt Reasonably Well
Jul 04Recent updates
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Screens Well But There Might Be A Catch
Nov 06The Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Half-Yearly Results Are Out And Analysts Have Published New Forecasts
Aug 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Looks Inexpensive But Perhaps Not Attractive Enough
Jul 22These 4 Measures Indicate That Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (BUSE:RICHTER) Is Using Debt Reasonably Well
Jul 04Here's Why We Think Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (BUSE:RICHTER) Is Well Worth Watching
Jun 16Investors Shouldn't Be Too Comfortable With Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's (BUSE:RICHTER) Earnings
Apr 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's (BUSE:RICHTER) Upcoming Dividend Will Be Larger Than Last Year's
Apr 11Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) Might Not Be As Mispriced As It Looks
Apr 09We Think Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (BUSE:RICHTER) Can Manage Its Debt With Ease
Mar 22Is There An Opportunity With Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.'s (BUSE:RICHTER) 45% Undervaluation?
Mar 04Does Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (BUSE:RICHTER) Have A Healthy Balance Sheet?
Dec 05Shareholder Returns
| RICHTER | HU Pharmaceuticals | HU Market | |
|---|---|---|---|
| 7D | -5.3% | -0.4% | 1.1% |
| 1Y | -9.8% | -10.0% | 31.4% |
Return vs Industry: RICHTER exceeded the Hungarian Pharmaceuticals industry which returned -11.6% over the past year.
Return vs Market: RICHTER underperformed the Hungarian Market which returned 32.5% over the past year.
Price Volatility
| RICHTER volatility | |
|---|---|
| RICHTER Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in HU Market | 9.2% |
| 10% least volatile stocks in HU Market | 2.8% |
Stable Share Price: RICHTER has not had significant price volatility in the past 3 months compared to the Hungarian market.
Volatility Over Time: RICHTER's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 10,943 | Gabor Orban | www.gedeonrichter.com |
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. The company offers women’s healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids, as well as Femtech, a digital therapeutic solution to enhance women’s lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases.
Gedeon Richter PLC Fundamentals Summary
| RICHTER fundamental statistics | |
|---|---|
| Market cap | Ft1.81t |
| Earnings (TTM) | Ft221.01b |
| Revenue (TTM) | Ft903.36b |
Is RICHTER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RICHTER income statement (TTM) | |
|---|---|
| Revenue | Ft903.36b |
| Cost of Revenue | Ft281.20b |
| Gross Profit | Ft622.16b |
| Other Expenses | Ft401.16b |
| Earnings | Ft221.01b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21k |
| Gross Margin | 68.87% |
| Net Profit Margin | 24.47% |
| Debt/Equity Ratio | 5.8% |
How did RICHTER perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/06 13:01 |
| End of Day Share Price | 2025/11/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gedeon Richter PLC is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Mather | Barclays |
| Samuel England | Berenberg |
| Victoria Lambert | Berenberg |